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Abstract 
Parkinson’s disease (PD) results from progressive degeneration of dopaminergic neu-
rons. Most PD cases are sporadic, but some have pathogenic mutation in the individual 
genes. Mutation of the leucine-rich repeat kinase-2 (LRRK2) gene is associated with familial 
and sporadic PD, as exemplified by G2019S substitution. While constitutive expression of 
mutant LRRK2 in transgenic mice fails to induce neuron death, transient expression of 
the disease gene by viral delivery causes a substantial loss of dopaminergic neurons in 
mice. To further assess LRRK2 pathogenesis, we created inducible transgenic rats ex-
pressing  human  LRRK2  with  G2019S  substitution.  Temporal  overexpression  of 
LRRK2G2019S in adult rats impaired dopamine reuptake by dopamine transporter (DAT) 
and thus enhanced locomotor activity, the phenotypes that were not observed in trans-
genic rats constitutively expressing the gene throughout life time. Reduced DAT binding 
activity is an early sign of dopaminergic dysfunction in asymptomatic subjects carrying 
pathogenic mutation in LRRK2. Our transgenic rats recapitulated the initiation process of 
dopaminergic dysfunction caused by pathogenic mutation in LRRK2. Inducible trans-
genic approach uncovered phenotypes that may be obscured by developmental com-
pensation  in  constitutive  transgenic  rats.  Finding  in  inducible  LRRK2  transgenic  rats 
would guide developing effective strategy in transgenic studies: Inducible expression of 
transgene may induce greater phenotypes than constitutive gene expression, particularly 
in rodents with short life time. 
Key words: LRRK2; Parkinson’s disease; rats; genetic model; dopamine transporter; dopaminergic 
neurons 
Introduction 
Parkinson’s  disease  (PD)  is  a  common  neuro-
degenerative disease caused by progressive degener-
ation of dopaminergic neurons in the substantia nigra 
pars  compacta  (SNpc).  How  neurons  degenerate  in 
PD  is  largely  unknown.  While  most  PD  cases  are 
sporadic, approximately 10% of the cases have genetic 
mutation  in  the  individual  genes,  including 
α-synuclein, parkin, DJ-1, pink1, and leucine-rich repeat 
kinase 2 (LRRK2) (1-6). Unlike mutation in the other 
PD genes, mutation of LRRK2 causes late-onset Par-
kinsonism  indistinguishable  from  idiopathic  PD 
(7-10), suggesting a role for LRRK2 in sporadic PD. 
Indeed, a common mutation in LRRK2 (G2019S sub-
stitution) occurs in sporadic PD (10), underscoring the 
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importance  of  LRRK2  for  understanding  PD  patho-
genesis. 
LRRK2 is a member of the newly defined ROCO 
protein family, which belongs to the Ras-GTPase su-
perfamily  (5,  6).  Limited  information  from  ortholo-
gous proteins in Dictyostelium Discoideum suggests a 
role  for  ROCO  proteins  in  regulating  cytoskeletal 
structures (11). Like the other ROCO proteins, LRRK2 
contains a conserved GTPase-like domain (Roc) and a 
mixed  lineage  kinase-like  kinase  domain  (5,  12). 
G2019S mutation located within the kinase domain of 
LRRK2 augments kinase activity implicated in LRRK2 
neurotoxicity (12-15). Mutation of LRRK2 within its 
Roc domain (R1440C substitution) also enhances its 
kinase  activity  (16),  suggesting  an  intrinsic  role  of 
kinase  activity  in  the  neurotoxicity.  To  understand 
LRRK2  pathogenesis,  a  critical  step  is  establishing 
animal models reproducing PD phenotypes observed 
in patients. Similar to the other genetic mouse models 
of PD (17-21), mutant mice with endogenous LRRK2 
deleted or with mutant LRRK2 introduced fail to de-
velop  dopaminergic  neuron  death  (22-29),  although 
some strains display dystrophy of dopaminergic neu-
rites  and  disturbance  to  dopaminergic  neurotrans-
mission (28, 29). Like transgenic mice, LRRK2 trans-
genic Drosophila of different strains also develops di-
verse phenotypes (30, 31). Phenotypic expression in 
LRRK2 transgenic animals largely depends on trans-
genic strains (22-31). Even though chromosomal posi-
tional effect on transgene expression is ameliorated by 
using  a  bulk  transgene,  such  as  bacterial  artificial 
chromosome (BAC), BAC transgenic mice expressing 
mutant LRRK2 develop varying phenotypes without 
neuronal  loss  (28,  32).  Such  findings  in  transgenic 
animals underscore the importance of diverse models 
for dissecting LRRK2 pathogenesis. 
To  further  assess  LRRK2  mutation,  we  devel-
oped  transgenic  rats  expressing  mutant  human 
LRRK2  in  a  controlled  manner.  Temporal,  but  not 
constitutive,  expression  of  human  LRRK2  with 
G2019S  substitution  enhanced  locomotor  activity  in 
aged  rats.  Microdialysis  analysis  of  living  rats  at-
tributed the enhanced locomotor activity to impaired 
dopamine reuptake by dopamine transporter (DAT). 
As a result of compromised DAT activity, ampheta-
mine-evoked  dopamine  release  and  ampheta-
mine-elicited  locomotor  activity  were  reduced  in 
mutant LRRK2 transgenic rats. Intriguingly, reduced 
DAT binding is the earliest indication of dopaminer-
gic dysfunction in asymptomatic subjects carrying a 
pathogenic mutation in LRRK2 (33). Thus, our trans-
genic rats recapitulated the initiation process of do-
paminergic  dysfunction  caused  by  mutation  in 
LRRK2. 
Materials and Methods 
Transgenic rat production and behavioral anal-
yses 
LRRK2 and tTA transgenic rats were produced 
by pronuclear injection as described previously (34). 
TRE-LRRK2G2019S  transgenic  rats  were  crossed  with 
CAG-tTA  transgenic  rats  to  produce  the  double 
transgenic  offspring  that  expressed  mutant  human 
LRRK2 in the absence of Doxycycline (Dox). To mimic 
constitutive gene expression, breeding rats and their 
offspring were not given Dox through their lifetime. 
To achieve temporal expression of LRRK2 transgene 
in adulthood, breeding rats and their offspring were 
constantly  given  Dox  in  drinking  water  (50µg/ml) 
until  the  double  transgenic  offspring  reached  5 
months of age. LRRK2 transgenic rats and the control 
rats  were  subject  to  open  field  activity  assay  (Med 
Associates),  which  measured  the  total  distance  and 
the total stereotypic move the rat made in 20 minutes. 
Elicited activities were measured at 5 minutes after 
administration of amphetamine (1mg/kg, I.p.) or 20 
minutes after administration of nomifensine (1mg/kg, 
I.p.).  Animal  use  followed  NIH  guidelines  and  the 
animal use protocol was approved by the Institutional 
Animal Care and Use Committees at Thomas Jeffer-
son University. 
Microdialysis and HPLC analysis 
As  described  previously  (35),  the  extracellular 
level  of  striatal  dopamine  was  measured  by  in-
tra-brain  microdialysis  combined  with  HPLC  in 
free-moving  rats.  Anesthetized  rats  were  implanted 
with a guide cannula the day before dialysis. On the 
following  day,  dialysis  probe  (BASi)  was  inserted 
through the guide cannula into the left striatum (co-
ordinates: 1 mm anterior to bregma; 2.6 mm left from 
sagittal line; 4 mm ventral to the skull). Continuous 
perfusion  was  maintained  with  modified  Ringer’s 
solution (147 mM Na+, 4 mM K+, 1.3 mM Ca2+, 1 mM 
Mg2+, and 155.6 mM CI-). Basal dopamine release was 
established within two hours when comparable levels 
of released dopamine were obtained in three consec-
utive samplings (20 minutes each). Amphetamine (1.3 
mM) and nomifensine (200 µM) were applied to dial-
ysis  solution  for  40  minutes  and  evoked  dopamine 
release was measured subsequently. Dopamine con-
centration in dialysis solution was instantly measured 
by HPLC. By the end of dialysis, the right striatum of 
dialyzed rats was dissected and homogenized in 0.1 
M  perchloric  acid  and  cleared  tissue  lysates  were 
measured by HPLC for the concentration of dopamine 
and  dopamine  metabolites.  Tissue  pellets  were  dis-




determined. Tissue contents of striatal dopamine were 
adjusted with protein concentration. HPLC analysis 
was done as described previously (36). 
Histology and stereological cell counting 
Immunostaining and stereological cell counting 
were done as described previously (36, 37). Rat’s brain 
was cut into serial sections of 30 µm on a Cryostat. 
Every  fourth  section  through  the  SNpc  and  every 
fourth section through the locus coeruleus (LC) were 
immunostained for TH (Pel-Freez; 1: 1000). TH posi-
tive  neurons  in  the  SNpc  and  in  the  LC  were  esti-
mated by stereological cell counting. Coronal sections 
of rat’s brain through SNpc and striatum were also 
immunostained with mouse monoclonal antibody to 
α-synuclein (1: 500; Chemicon), chicken antibody to 
ubiquitin (1: 1000; Sigma), or rabbit polyclonal anti-
body to phospho-tau (1: 500; Sigma). 
[
3H]-dopamine uptake assay 
The  assay  was  performed  as  described  previ-
ously (38). The human neuroblastoma SH-SY5Y cells 
that  stably  expressed  human  DAT-EGFP-C1  were 
seeded into 96-well plates and were then transfected 
with  LRRK2  constructs  using  Lipofectamine  2000 
(Invitrogen,  CA).  Two  days  following  transfection, 
cells  were  washed  with  PBSCM  (PBS  with  0.1mM 
CaCl2, 1 mM MgCl2), and were incubated with 50 nM 
[3H]-dopamine plus varying concentrations of unla-
beled dopamine for 5 min at room temperature. Re-
tained radioactivity in cells was determined by liquid 
scintillation  spectrometry.  Data  from  triplicate  sam-
ples  were  analyzed  according  to  the  Michae-
lis-Menten  kinetic  equation  using  GraphPad  Prism 
4.0. 
Results 
Enhanced locomotor activity in aged rats ex-
pressing mutant LRRK2 in adulthood 
To further examine the pathogenesis of mutation 
in LRRK2, we created transgenic rats overexpressing a 
mutant LRRK2 with G2019S substitution (34). Trans-
genic studies of amyotrophic lateral sclerosis suggest 
that mice and rats develop diverse phenotypes, even 
if the same disease gene is overexpressed (37, 39). Rats 
confer advantages over mice in behavior tests that are 
crucial to the modeling of neurological diseases such 
as  PD  (40,  41).  To  increase  the  diversity  of  animal 
models for PD, we chose rats to model the phenotypes 
of  pathogenic  mutation  in  LRRK2.  Since  develop-
mental  compensation  for  transgene  expression  may 
compromise  phenotypic  expression  in  transgenic 
animals, we used a Tet-inducible system to express 
mutant  LRRK2  transgene  temporally  in  adult  rats 
(34). As described previously (34), one transgenic line 
carrying two copies of LRRK2 transgene was estab-
lished and this line expressed mutant human LRRK2 
robustly in the midbrain when crossed onto CAG-tTA 
transgenic background. 
The mutant LRRK2 transgene was driven by the 
TRE promoter and thus its expression depends on tTA 
activation and is subject to Dox regulation (34). In the 
absence of Dox, mutant LRRK2 transgene was con-
tinuously and fully expressed (34), exhibiting a con-
stitutive expression pattern (Fig. 1A). To obtain tem-
poral overexpression of mutant LRRK2 in adult rats, 
we  supplied  transgenic  rats  with  Dox  in  drinking 
water during embryonic and postnatal development 
such that the mutant LRRK2 transgene was constantly 
suppressed  from  expression  in  transgenic  rats  (34). 
Dox-treated rats were deprived of Dox at the age of 5 
months,  and  they  soon  began  to  express  mutant 
LRRK2 after Dox withdrawal (Fig. 1A). Constitutive 
overexpression  of  mutant  LRRK2  failed  to  induce 
behavioral phenotypes in transgenic rats (Fig. 1B). In 
contrast  to  constitutive  overexpression,  temporal 
overexpression  of  mutant  LRRK2  caused  abnormal 
locomotor activity in aged, but not in young, trans-
genic rats (Fig. 1B). The results suggest that temporal 
gene expression uncovered the phenotypes obscured 
by developmental compensation. 
Unaltered number of dopaminergic neurons and 
unaltered content of striatal dopamine in LRRK2 
transgenic rats 
PD  is  characterized  by  progressive  loss  of  do-
paminergic neurons in the SNpc (42). We then exam-
ined  dopaminergic  neurons  by  stereological  cell 
counting.  Neither  constitutive  nor  temporal  overex-
pression of mutant LRRK2 altered the number of do-
paminergic  neurons  in  transgenic  rats  at  advanced 
ages (Fig. 2A-1G). Noradrenergic neurons in the locus 
coeruleus (LC) are often lost at the early stages of PD 
(43). We also assessed the TH-positive neurons in the 
LC  and  found  no  loss  of  the  neurons  in  aged  rats 
constitutively  or  temporally  expressing  mutant 
LRRK2 (Fig. 2H). The axonal terminals of dopamin-
ergic neurons are the primary targets of degeneration 
in PD (44). We measured the contents of the neuro-
transmitter  dopamine  in  the  striatum,  but  did  not 
detect  any  change  to  the  total  striatal  dopamine  in 
mutant  LRRK2  transgenic  rats,  although  the  trans-
genic  rats  expressing  mutant  LRRK2  temporally  in 
adulthood developed abnormal locomotor activity in 
advanced ages (Figs. 1B and 2I-2K). Proteinopathy is 
considered a characteristic of PD (42, 45). In our mu-




inclusion  positive  for  α-synuclein,  ubiquitin,  or 
phosphorylated Tau.  
Impaired reuptake of dopamine in aged rats 
overexpressing mutant LRRK2 in adulthood 
Temporal overexpression of mutant LRRK2 en-
hanced locomotor activity in aged rats (Figs. 1 and 4), 
indicating that dopaminergic neurotransmission was 
altered. In the aged rats, however, the content of stri-
atal dopamine was unaltered (Fig. 2I), suggesting that 
dopamine  synthesis  and  storage  may  not  be  inter-
rupted by temporal overexpression of mutant LRRK2. 
The extracellular level of dopamine released from the 
neuronal terminals is virtually related to dopaminer-
gic function. Using intra-brain microdialysis, we as-
sessed  dopamine  release  in  the  striatum  of 
free-moving transgenic rats and detected a significant 
increase in dopamine release in temporally, but not in 
constitutively, mutant LRRK2-expressing rats (Fig. 3). 
Enhanced locomotor activity in mutant LRRK2 rats is 
attributable  to  elevated  levels  of  dopamine  in  the 
synaptic  cleft.  Elevation  of  extracellular  dopamine 
levels may result from increased release or reduced 
reuptake of dopamine. Nomifensine, a selective DAT 
inhibitor, increased dopamine release to comparable 
levels between the mutant LRRK2 transgenic rats and 
the  control  rats  (Fig.  3A).  This  increased  release  of 
dopamine upon nomifensine stimulation was signifi-
cantly reduced by temporal, but not by constitutive, 
expression  of  mutant  LRRK2  (Fig.  3B).The  results 
suggest that dopamine release was unaltered but that 
dopamine  reuptake  was  impaired  in  the  mutant 
LRRK2 rats. Amphetamine is structurally similar to 
dopamine and has a higher affinity for DAT and ve-
sicular monoamine transporter type 2 (VMAT2) than 
dopamine. The affinity of amphetamine is higher for 
DAT than for VMAT2. Amphetamine-evoked release 
of dopamine was compromised in transgenic rats ex-
pressing  mutant  LRRK2  in  adulthood  (Fig.  3),  con-
firming that DAT activity was impaired in the mutant 
rats  at  advanced  ages.  Accordingly,  amphetamine- 
and  nomifensine-elicited  locomotor  activity  was  re-
duced in aged rats that temporally, but not constitu-
tively,  overexpressed  mutant  LRRK2  (Fig.  4A-4D). 
Collectively, the results suggest that DAT activity was 




Figure 1. Temporal overexpression of mutant LRRK2 alters locomotor activity in aged rats. A, Immunoblotting 
revealed a full recovery of LRRK2 transgene expression in the brainstem after Doxycycline (Dox) withdrawal. Brain 
tissues  were  dissected  from  transgenic  rats  carrying  CAG-tTA  and  TRE-hLRRK2
G2019S-HA  transgenes.  The  dou-
ble-transgenic rats were untreated with Dox throughout their lives (constitutive expression) or treated with Dox (50 
µg/ml in drinking water) from the embryonic stage to 5 months of age (temporal expression). Human LRRK2 was 
detected with an antibody to HA tag fused to the C-terminal of the mutant human LRRK2. GAPDH immunoreactivity 
was detected as a control for equal loading. B, Open field activity assay revealed an increase in locomotor activity in 
aged rats temporally, but not constitutively, overexpressing the mutant LRRK2. Data are means + SEM (n = 10). * p < 





Figure  2.  Overexpression  of  mutant  LRRK2 
causes no loss of nigral dopaminergic neurons 
and  striatal  dopamine  contents  in  aged  rats. 
A-F, Representative photos of low (A-C) or high 
(D-F) magnification show the SNpc of transgenic 
rats at 18 months of age. Transgenic rats carried a 
CAG-tTA single transgene (1: tTA), or CAG-tTA and 
TRE-LRRK2
G2019S  double  transgenes  (2  and  3: 
LRRK2). Constitutive expression of mutant LRRK2 
(2:  constitutive  LRRK2)  was  achieved  by  with-
holding Dox throughout rat’s lives, and temporal 
expression of the transgene (3: temporal LRRK2) 
was achieved by withdrawing Dox from rats at the 
age of 5 months. G, H, Stereological cell counting 
revealed  no  loss  of  TH-positive  neurons  in  the 
SNpc and locus coeruleus (LC). Data are means ± 
SEM (n = 7). I-K, HPLC revealed the contents of 
striatal  dopamine  (DA)  and  DA  metabolites 
(DOPAC  and  HVA)  in  transgenic  rats.  Data  are 
means ± SEM (n = 10). Experimental group number 
















Figure 3. Overexpression of mutant LRRK2 impairs DA reuptake in aged rats. A, Intra-brain microdialysis revealed 
the extracellular levels of DA in the striatum of free-moving rats at 18 months of age. Basal DA release was estab-
lished in living rats when three consecutive samplings resulted in a sustainable level of DA in dialysates in the absence 
of stimulation. The peaks of stimulated DA release were detected after nomifensine (200 µM) or amphetamine (1.3 
mM) was applied to dialysate. Data are means ± SEM (n = 8). * p < 0.05 compared to CAG-tTA single transgenic rats 
(tTA). B, Increased peak of stimulated DA release was calculated for each animal by subtracting basal release from 







Figure 4. Temporal overexpression of mutant LRRK2 increases spontaneous, but reduces evoked, locomotor 
activity in aged rats. A, B, Open field activity assay measured locomotor activity in transgenic rats treated or un-
treated with nomifensine or amphetamine. Transgenic rats (18 months old) were subject to behavior test. C, D, 
Increased locomotor activity in response to drug stimulation was calculated by subtracting spontaneous activity 









No direct interaction of mutant LRRK2 with do-
pamine transporter 
Microdialysis revealed that dopamine reuptake 
was impaired in aged rats expressing mutant LRRK2 
temporally in adulthood (Fig. 3). To further assess the 
potential interaction of mutant LRRK2 with DAT, we 
used the neuroblastoma cells SH-SY5Y as an in vitro 
model of dopaminergic neurons. The SH-SY5Y cells 
that  were  stably  transfected  with  DAT-expressing 
plasmid were transiently transfected with normal or 
mutant LRRK2-expressing constructs. In the presence 
of forcedly overexpressed LRRK2 variants, dopamine 
uptakes  were  determined  and  no  significant  differ-
ence  between  LRRK2  variants  tested  was  observed 
(Fig. 5). The results suggest that normal and mutant 
LRRK2 do not interact with DAT directly. 
 
Figure  5.  Overexpression  of  LRRK2  variants  has  no 
direct effect on the transport activity of DAT heter-
ogeneously expressed in dopaminergic cells. SH-SY5Y 
cells stably expressing GFP-DAT were seeded in 96-well 
plates and transiently transfected with indicated con-
structs.  [
3H]-DA  uptake  was  determined  2  days  after 
transfection.  Data  were  analyzed  according  to  the 
Michaelis-Menten  kinetics  using  GraphPad  Prism  4.0 
software. The Vmax and Km values derived from the re-
gression curves were not significantly different. 





Because G2019S mutation in LRRK2 is observed 
in both the familial and sporadic PD (10), we chose 
LRRK2G2019S as an example of LRRK2 mutations for 
transgenic  study.  Temporal,  but  not  constitutive, 
overexpression of the mutant LRRK2 induced unex-
pected  phenotypes,  including  enhanced  locomotor 
activity  and  impaired  dopamine  reuptake.  Altered 
locomotor activity in transgenic rats was attributed to 
elevated levels of extracellular dopamine revealed by 
intra-brain  microdialysis.  The  extracellular  level  of 
dopamine is an outcome of the balance between do-
pamine  release  and  reuptake.  Blocking  dopamine 
reuptake with the DAT-specific inhibitor nomifensine 
had  a  reduced  effect  on  extracellular  dopamine. 
DAT-mediated reuptake of dopamine can be reverted 
by  amphetamine.  In  LRRK2  transgenic  rats,  am-
phetamine had a reduced effect on the extracellular 
level of released dopamine. Pharmacologic analyses 
suggest that DAT-mediated dopamine reuptake was 
impaired in mutant LRRK2 transgenic rats. The be-
havioral  change  was  observed  in  aged,  but  not  in 
young,  transgenic  rats,  implying  that  DAT  activity 
was impaired gradually as mutant LRRK2 was over-
expressed.  The  phenotypes  were  induced  by  tem-
poral,  but  not  by  constitutive,  overexpression  of 
pathogenically mutated LRRK2, although the expres-
sion  levels  of  mutant  LRRK2  were  comparable  be-
tween temporal and constitutive expression patterns. 
The findings suggest that damage to DAT activity was 
an  indirect  effect  of  mutant  LRRK2.  This  notion  is 
further supported by in vitro analysis, which did not 
detect  any  direct  interaction  of  mutant  or  normal 
LRRK2  with  DAT.  Temporal  expression  of  mutant 
LRRK2  in  adult  rats  caused  gradual  damage  to 
DAT-mediated dopamine reuptake. 
Neuronal death in PD is considered a dying-back 
process  and  the  neurites  of  dopaminergic  cells  are 
thought  to  be  the  primary  targets  for  degeneration 
(28, 44). Most studies of genetic PD models reveal no 
dopaminergic neuron death, but do reveal damage to 
dopamine neurotransmission (18, 23, 29, 32, 46). As 
impaired D2 autoreceptor function is revealed in DJ-1 
knockout  and  in  LRRK2  knockin  mice  (18,  29), 
DAT-mediated dopamine reuptake was, for the first 
time, revealed impaired in a transgenic model for PD. 
Our results, though unexpected, are consistent with 
clinical findings in mutant LRRK2 carriers who dis-
play  reduced  DAT  binding  at  asymptomatic  stages 
(33). Elevation of extracellular dopamine may cause 
oxidative  damage  to  dopaminergic  neurites  and  is 
possibly  an  early  event  in  PD  pathogenesis.  Com-
pared  to  constitutive  gene  expression,  temporal 
overexpression  of  mutant  LRRK2  in  adult  rats  in-
duced  a  greater  phenotype,  possibly  because  it 
avoided  developmental  compensation  for  transgene 
expression. Our finding may help interpret why tran-
sient expression of PD genes by viral delivery often 
produces great disease phenotypes that could not be 
reproduced by constitutive expression of the disease 
genes in transgenic animals (26, 28, 29, 32, 47, 48). 
Inducible  LRRK2  transgenic  rats  recapitulated 
the early pathology observed in asymptomatic sub-
jects  who  carry  pathogenic  mutation  in  LRRK2. 
However, our transgenic rats did not develop dopa-
minergic  neurodegeneration  in  their  lifetime.  The 
limited  copy  of  mutant  LRRK2  transgene  (only  2 
copies) may yield insufficient disease protein, which 
was  below  the  threshold  to  induce  dopaminergic 
neuron death in a rat’s lifetime. Phenotypic expres-
sion in rats may be improved by increasing expression 
of the LRRK2 transgene. As PD is considered a mul-
tifactorial disease, multiple genetic and environmen-
tal factors may interact to induce dopaminergic neu-
ron death (37). Indeed, varied disease penetrance and 
varied onset time are observed in the subjects carrying 
pathogenic  mutation  in  LRRK2  (9),  favoring  multi-
factorial pathogenesis in PD. Mutation of a single PD 
gene, particularly with low yield, may not be suffi-
cient to induce neuron death within the short lifespan 
of rodents. Based on the multifactorial pathogenesis of 
PD,  a  combination  of  multiple  disease  factors  (in-
cluding environmental and genetic factors) will im-
prove phenotypic expression in animal models. 
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